Back to results
US 2023/0053604 A1Published application
Methods of treating myeloproliferative disorders
AssigneeConstellation Pharmaceuticals, Inc.
InventorsAdrian Senderowicz, Michael Cooper
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to the use of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide, and pharmaceutically acceptable salts thereof, for treating myelofibrosis.
Claims22
A method of treating myelofibrosis in a subject comprising administering to the subject from 100 mg/day to 300 mg/day of 2-((4S)-6-(4-chlorophenyl)-1-methyl-4H-benzo[c]isoxazolo[4,5-e]azepin-4-yl)acetamide.
2-11. (canceled)
13-20. (canceled)
(canceled)
24-26. (canceled)
(canceled)
Dependencies are inferred from the claim text.